프로젠 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 유한양행, was filed 20 Jul 2026.
프로젠: what insiders have been doing
Every trade that managers of 프로젠 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 27 October 2026, brought 15 filings signed by 8 insiders.
On the market, 7 insiders bought (12 purchases totalling €543k) while 1 insider sold (1 sale). The totals do not cover 10 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 major shareholders, 2 chief executives and 1 board member among the declarants. Biggest ticket of the year: €526k, bought by 에스엘바이젠 and made public on 31 March 2026.
The last insider purchase was made public on 20 July 2026, 113 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 2,651 companies) published 7 filings over the same period, against 15 filings here. Looking back to 2023, when coverage begins, insiders filed 40 purchases and 13 sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySale+3 other insiders
Since the insiders bought
- -26.0%Entry 2,830.00 · Close at T+90 2,095.00
- -26.0%Entry 2,830.00 · Close at T+90 2,095.00
- -26.0%Entry 2,830.00 · Close at T+90 2,095.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- Other0DART
- 3,655,897 sharesShareKRXDART:20260720000028Canonical exit: 18 Oct 2026 (T+90)
- 238,966 sharesShareKRXDART:20260716000578Canonical exit: 14 Oct 2026 (T+90)
- 529,791 sharesShareKRXDART:20260716000526Canonical exit: 14 Oct 2026 (T+90)
- 752,923 sharesKRXDART:20260716000524Canonical exit: 14 Oct 2026 (T+90)
- 1,151,860 sharesKRXDART:20260716000470Canonical exit: 14 Oct 2026 (T+90)
- 7,546 sharesShareKRXDART:20260716000660Canonical exit: 14 Oct 2026 (T+90)
- 7,546 sharesShareKRXDART:20260716000643Canonical exit: 14 Oct 2026 (T+90)
- 1,002 shares@ ₩5,250.3593100.0% of flowShareKRXDART:20260514000154Canonical exit: 14 Dec 2025 (T+90)
- 5,000 shares@ ₩4,793.400.023% mcap100.0% of flowShareKRXDART:20260513000088Canonical exit: 4 Aug 2026 (T+90)
- ShareKRXDART:20260507000619
- 246,119 sharesKRXDART:20260406002707
- ShareKRXDART:20260331001967
- 167,000 shares@ ₩5,474.00100.0% of flowShareKRXDART:20260331001938Canonical exit: 28 Jun 2026 (T+90)
- 599,742 sharesKRXDART:20260108000329Canonical exit: 31 Mar 2026 (T+90)
- 16,380 sharesKRXDART:20260108000273Canonical exit: 31 Mar 2026 (T+90)
- ●Executives0DART
- 285,637 sharesKRXDART:20250707000021
- ●Executives0DART
- 78,814 sharesShareKRXDART:20250523000539
- 100,996 sharesKRXDART:20250523000491
- 1,469 sharesShareKRXDART:20250502000185Canonical exit: 31 Jul 2025 (T+90)
- 1,469 sharesShareKRXDART:20250502000164Canonical exit: 31 Jul 2025 (T+90)
- 1,469 sharesShareKRXDART:20250502000156Canonical exit: 31 Jul 2025 (T+90)
- 2,300,739 sharesKRXDART:20250430001228Canonical exit: 24 Jul 2025 (T+90)
25 of 72 declarations
About 프로젠
Progen is a healthcare and pharmaceutical company listed on the XKRX. It focuses on developing innovative treatments and therapeutic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
